ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy

Схожие документы

• Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
  по: Palmieri, Carlo, et al.
  Опубликовано: (2015)
• Weekly Paclitaxel/Carboplatin/Trastuzumab Therapy Improves Pathologic Complete Remission in Aggressive HER2-Positive Breast Cancers, Especially in Luminal-B Subtype, Compared With a Once-Every-3-Weeks Schedule
  по: Yu, Ke-Da, et al.
  Опубликовано: (2013)
• Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab
  по: Ding, Jinhua, et al.
  Опубликовано: (2017)
• Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
  по: E. V. Lubennikova, et al.
  Опубликовано: (2021-12-01)
• Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer
  по: Yu, Ke-Da, et al.
  Опубликовано: (2012)